The USMCA Will Keep Drug Prices Out of Reach for Patients, But Congress Can Fix It | Association for Accessible Medicines
AAM All Access Podcast - AAM CEO Dan Leonard convenes industry and policy experts to explore why the Inflation Reduction Act (f/k/a Build Back Better) reduces generic and biosimilar competition.

The USMCA Will Keep Drug Prices Out of Reach for Patients, But Congress Can Fix It

The USMCA Creates New Barriers, Delays Patient Access to Affordable Medicines — Especially Biosimilars.

The Agreement would delay U.S. patient access to competition from low-cost, high-quality generic and biosimilar medicines, and fails to include strong incentives for their approval and uptake. 

Read Full Brief

 

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.